Acrivon Therapeutics Inc
ACRV1.265USD
+0.005+0.40%
交易中 （美东）报价延迟15分钟
39.66M总市值
亏损市盈率 TTM
关于 Acrivon Therapeutics Inc 公司
Acrivon Therapeutics, Inc. 是一家临床阶段生物制药公司，致力于开发精准肿瘤药物。该公司利用其精准医疗平台 Acrivon Predictive Precision Proteomics (AP3) 开发其肿瘤候选药物管线。其主要候选药物 ACR-368 是一种选择性小分子抑制剂，在完整细胞中分别以低于个位数 nM 和个位数 nM 的效力靶向 CHK1 和 CHK2，目前正处于一项可能注册的 2 期临床试验中，涉及多种实体肿瘤类型。利用其 AP3 平台，该公司开发了一种针对 ACR-368 的预测性 OncoSignature 测试，称为 ACR-368 OncoSignature，可以预测患者对 ACR-368 单药治疗的反应，从而大幅提高临床总体缓解率 (ORR)，并有可能加快药物开发。其临床前项目 ACR-2316 正在 IND 支持研究中取得进展。它是一种新型的双重 WEE1 和 PKMYT1 抑制剂小分子开发候选药物。
公司简介
公司代码ACRV
公司名称Acrivon Therapeutics Inc
上市日期Nov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
员工数量75
证券类型Ordinary Share
年结日Nov 15
公司地址480 Arsenal Way, Suite 100
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02472
电话16172078979
网址https://acrivon.com/
公司代码ACRV
上市日期Nov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mrs. Mary-Alice Miller, J.D.
Mrs. Mary-Alice Miller, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
--
-100.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
持股股东
持股股东
占比
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
股东类型
持股股东
占比
Venture Capital
26.60%
Hedge Fund
13.15%
Corporation
12.27%
Individual Investor
8.56%
Investment Advisor
7.97%
Investment Advisor/Hedge Fund
6.91%
Research Firm
0.36%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
24.12%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
142
23.71M
75.61%
-5.03M
2025Q1
146
29.35M
93.70%
-2.39M
2024Q4
141
30.19M
96.96%
-1.30M
2024Q3
129
30.21M
97.90%
-1.16M
2024Q2
124
30.86M
100.26%
+1.75M
2024Q1
110
20.99M
93.28%
+95.57K
2023Q4
96
21.08M
95.04%
+130.06K
2023Q3
91
21.13M
95.90%
+687.39K
2023Q2
85
20.62M
94.10%
+177.16K
2023Q1
71
22.16M
102.70%
+6.28M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
8.34M
26.6%
--
--
Mar 31, 2025
Chione, Ltd.
3.85M
12.27%
--
--
Jun 30, 2024
Blume-Jensen (Peter)
2.21M
7.04%
-79.67K
-3.49%
May 21, 2025
Sands Capital Ventures LLC
2.12M
6.77%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.90M
6.05%
-224.13K
-10.57%
Mar 31, 2025
Wellington Management Company, LLP
888.13K
2.83%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
844.91K
2.69%
-5.84K
-0.69%
Mar 31, 2025
The Vanguard Group, Inc.
674.79K
2.15%
+3.17K
+0.47%
Mar 31, 2025
Marshall Wace LLP
450.39K
1.44%
-147.40K
-24.66%
Mar 31, 2025
Acorn Capital Advisors, LLC
405.24K
1.29%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
iShares Russell 2000 ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
iShares Biotechnology ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Global X Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
